The U.S. FDA authorized Moderna’s mRESVIA respiratory syncytial virus vaccine for use in additional adult populations aged 18 to 59 at risk for RSV infection, broadening availability beyond older adults. The approval follows recent successes of Moderna's vaccines and provides more preventive options against a significant respiratory pathogen.